Roche makes progress in developing new drug for cancer immunotherapy

The FDA has presented the breakthrough therapy status of the combination of two Roche antibodies - the old PD-L1 checkpoint inhibitor Tecentriq and a new antibody that targets TIGIT tiragolumab. It could be used for patients with advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression.

Tiragolumab is a monoclonal antibody that targets TIGIT receptor and is also the first drug in its class which received a regulatory approval. The regulatory agency approval is based on data of CITYSCAPE Phase 2 study. The study has shown that the combination of the two antibodies reduced tumors in 31% of patients, which in turn was double in comparison with Tecentriq monotherapy. Tiragolumab is one of the most promising and innovative drugs in the Swiss group. Despite the fact that the drug had previously demonstrated almost zero response to therapeutic use mono mode, but it worked well in a sample of patients with lung cancer in the combined use with Tecentriq.

Source: PHARMAPHORUM